SEARCH

SEARCH BY CITATION

To the Editors:

We thank Dr. Aslanidis and colleagues for their comments on our study and for sharing their data on neutropenia with infliximab in inflammatory arthritis. We agree that their observations seem to concur with ours, and that this is a potential complication of anti-TNF therapy that needs monitoring.

Richard Hastings MD, PhD*, Tina Ding MA (Cantab), MSc (Rheum), MRCP*, Chris Deighton MD, FRCP*, * Royal Derby Hospital, Derby, UK.